Substitute for form 1449B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT *(Use as many sheets as necessary)*			Application Number	10/533,844
			Filing Date	May 4, 2005
			First Named Inventor	Hagen, Frederick S.
			Art Unit	1649
			Examiner Name	Olga N. Chernyshev
Sheet	1	of 5	Attorney Docket Number	017881-001010US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number — Number Kind Code[2] (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-5,604,102	02-18-1997	McConlogue et al.	
	AB	US-5,658,754	08-19-1997	Kawasaki	
	AC	US-6,153,380	11-28-2000	Nolan et al.	
	AD	US-6,175,057	01-16-2001	Mucke et al.	
	AE	US-6,267,962	07-31-2001	Hart et al.	
	AF	US-6,365,634	04-02-2002	Russell et al.	
	AG	US-6,420,110	07-16-2002	Gyuris et al.	
	AH	US-6,440,698	08-27-2002	Gurney et al.	
	AI	US-2002/0127564	09-12-2002	Nolan	
	AJ	US-2006/0275833	12-07-2006	Hagen	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document — Country Code[3]	Number[4]	Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	AK	PCT	WO 98/21589	A1	05-22-1998	University of Pennsylvania		☐
	AL	PCT	WO 98/39483	A1	09-11-1998	Ventana Genetics, Inc.		☐
	AM	PCT	WO 99/24617	A1	05-20-1999	Ventana Genetics, Inc.		☐
	AN	PCT	WO 01/49097	A2	07-12-2001	Bienkowski et al.		☐
	AO	PCT	WO 03/57165	A2	07-17-2003	The Rockefeller University		☐
	AP	PCT	WO 04/18997	A2	03-04-2004	Neurogenetics, Inc.		☐
	AQ	PCT	WO 04/42074	A2	05-21-2004	Icogen Corp.		☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT *(Use as many sheets as necessary)*				Application Number	10/533,844
				Filing Date	May 4, 2005
				First Named Inventor	Hagen, Frederick S.
				Art Unit	1649
				Examiner Name	Olga N. Chernyshev
Sheet	2	of	5	Attorney Docket Number	017881-001010US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	AR	BROWN, " Metal-recognition by repeating polypeptides," *Nat. Biotechnol.* 15:269-272 (1997).	☐
	AS	CEDAZO-MINGUEZ *et al.,* "Nicergoline stimulates protein kinase C mediated α-secretase processing of the amyloid precursor protein in cultured human neuroblastoma SH-SY5Y cells," *Neurochem. Int.* 35:307-315 (1999).	☐
	AT	CULL *et al.,* "Screening for receptor ligands using large libraries of peptides linked to the C terminus of the *lac* repressor," *Proc. Natl. Acad. Sci. USA* 89:1865-1869 (1992).	☐
	AU	DE STROOPER *et al.,* "Exchanging the extracellular domain of amyloid precursor protein for horseradish peroxidase does not interfere with α-secretase cleavage of the β-amyloid region, but randomizes secretion in Madin-Darby canine kidney cells," *J. Biol. Chem.* 270:30310-30314 (1995).	☐
	AV	FIELDS and SONG, "A novel genetic system to detect protein-protein interactions," *Nature* 340:245-246 (1989).	☐
	AW	GAMES *et al.,* "Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein," *Nature* 373:523-527 (1995).	☐
	AX	GILCHRIST *et al.,* "Use of peptides-on-plasmids combinatorial library to identify high-affinity peptides that bind rhodopsin," *Methods Enzymol.* 315:388-404 (2000).	☐
	AY	GOTZ *et al.,* "Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Aβ42 fibrils," *Science* 293:1491-1495 (2001).	☐
	AZ	HARTLEY *et al.,* "Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons," *J. Neurosci.* 19:8876-8884 (1999).	☐
	BA	HSIAO *et al.,* "Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice," *Science* 274:99-102 (1996).	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT *(Use as many sheets as necessary)*	Application Number	10/533,844
	Filing Date	May 4, 2005
	First Named Inventor	Hagen, Frederick S.
	Art Unit	1649
	Examiner Name	Olga N. Chernyshev
Sheet 3 of 5	Attorney Docket Number	017881-001010US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	BB	KANG *et al.,* "The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor," *Nature* 325:733-736 (1987).	☐
	BC	KAWARABAYASHI *et al.,* "Age-dependent changes in brain, CSF, and plasma amyloid β protein in the Tg2576 transgenic mouse model of Alzheimer's disease," *J. Neurosci.* 21:372-381 (2001).	☐
	BD	KINSELLA *et al.* "Retrovirally delivered random cyclic peptide libraries yield inhibitors of interleukin-4 signaling in human B cells," *J. Biol. Chem.* 277:37512-37518 (2002).	☐
	BE	KJAERGAARD *et al.,* "Novel Zn^{2+}-chelating peptides selected from a fimbria-displayed random peptide library," *Appl. Environ. Microbiol.* 67:5467-5473 (2001).	☐
	BF	LABEAN and KAUFFMAN, "Design of synthetic gene libraries encoding random sequence proteins with desired ensemble characteristics," *Protein Sci.* 2:1249-1254 (1993).	☐
	BG	LAMMICH *et al.,* "Constitutive and regulated α-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease," *Proc. Natl. Acad. Sci. USA* 96:3922-3927 (1999).	☐
	BH	LOPEZ-PEREZ *et al.,* "Proprotein convertase activity contributes to the processing of the Alzheimer's β-amyloid precursor protein in human cells: evidence for a role of the prohormone convertase PC7 in the constitutive α-secretase pathway," *J. Neurochem.* 73:2056-2062 (1999).	☐
	BI	LU *et al.,* "Expression of thioredoxin random peptide libraries on the *Escherichia coli* cell surface as functional fusions to flagellin: a system designed for exploring protein-protein interactions," *Biotechnology* 13:366-372 (1995).	☐
	BJ	MAZUR-KOLECKA *et al.,* "Accumulation of Alzheimer amyloid-peptide in cultured myocytes is enhanced by serum and reduced by cerebrospinal fluid," *J. Neuropathol. Exp. Neurol.* 56(3):263-272, Abstract only, (1997).	☐
	BK	MILLER *et al.,* "Use of retroviral vectors for gene transfer and expression," *Methods Enzymol.* 217:581-599 (1993).	☐
	BL	MULLAN *et al.,* "A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of β-amyloid," *Nat. Genet.* 1:345-347 (1992).	☐

Examiner Signature		Date Considered	

Substitute for form 1449B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT *(Use as many sheets as necessary)*			Application Number	10/533,844
			Filing Date	May 4, 2005
			First Named Inventor	Hagen, Frederick S.
			Art Unit	1649
			Examiner Name	Olga N. Chernyshev
Sheet	4	of	5	Attorney Docket Number	017881-001010US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	BM	MURTHY, "Characterization of the interleukin 3 receptor," *Exp. Hematol.* 18(1):11-17 (1990).	☐
	BN	NILSBERTH *et al.,* "The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation," *Nat. Neurosci.* 4:887-893 (2001).	☐
	BO	NILSSON *et al.,* "α-1-antichymotrypsin promotes β-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease," *J. Neurosci.* 21:1444-1451 (2001).	☐
	BP	NORMAN *et al.,* "Genetic selection of peptide inhibitors of biological pathways," *Science* 285:591-595 (1999).	☐
	BQ	PARVATHY *et al.* "Alzheimer's amyloid precursor protein α-secretase is inhibited by hydroxamic acid-based zinc metalloprotease inhibitors: similarities to the angiotensin converting enzyme secretase," *Biochemistry* 37:1680-1685 (1998).	☐
	BR	PONCET, "CD24, a glycosylphosphatidylinositol-anchored molecules is transiently expressed during the development of human central nervous system and is a marker of human neural cell lineage tumors," *Acta. Neuropathol.* 91(4):400-408, Abstract only, (1996).	☐
	BS	RIAN *et al.,* "A signal sequence trap based on cell enrichment using anti-CD19 antibody coated magnetic beads," *Scand. J. Immunol.* 54:280-284 (2001).	☐
	BT	SCOTT and SMITH, "Searching for peptide ligands with an epitope library," *Science* 249:386-390 (1990).	☐
	BU	SELKOE, "Alzheimer's disease: genes, proteins, and therapy," *Physiol. Rev.* 81:741-766 (2001).	☐
	BV	SELKOE, "Alzheimer's disease is a synaptic failure," *Science* 298:789-791 (2002).	☐
	BW	SINHA, *et al.,* "Purification and cloning of amyloid precursor protein β-secretase from human brain," *Nature* 402:537-540 (1999).	☐
	BX	SISODIA, "β-amyloid precursor protein cleavage by a membrane-bound protease," *Proc. Natl. Acad. Sci. USA* 89:6075-6079 (1992).	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT *(Use as many sheets as necessary)*	Application Number	10/533,844
	Filing Date	May 4, 2005
	First Named Inventor	Hagen, Frederick S.
	Art Unit	1649
	Examiner Name	Olga N. Chernyshev
Sheet　5　of　5	Attorney Docket Number	017881-001010US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	BY	STEINER and HAASS, "Intramembrane proteolysis by presenilins," *Nat. Rev. Mol. Cell. Biol.* 1:217-224 (2000).	☐
	BZ	WESTERMAN *et al.,* "The relationship between Aβ and memory in the Tg2576 mouse model of Alzheimer's disease," *J. Neurosci.* 22:1858-1867 (2002).	☐
	CA	WILSON *et al.,* "The use of mRNA display to select high-affinity protein-binding peptides," *PNAS* 98:3750-3755 (2001).	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

60943586 v1